- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00056797
Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV
A Randomized Controlled Study Testing the Efficacy of Immunotherapies to Control Plasma HIV RNA Concentrations Upon Interruption of Highly Active Antiretroviral Therapy (HAART).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
While the advent of highly active antiretroviral therapy (HAART) has contributed to the increasing control of HIV infection and viral replication, ultimate control of HIV infection will require the development of effective HIV-specific immunity in HIV infected individuals.
This trial will evaluate the use of the ALVAC vCP1452 vaccine in combination with IL-2 to increase HIV-specific immune responses in HIV infected patients. ALVAC vCP1452 vaccine is a recombinant canarypox HIV vaccine that is administered as a monthly intramuscular injection. The IL-2 is self administered as a daily subcutaneous injection at a low, non-toxic dose (2 million units).
Participants in this study are randomized to receive either ALVAC and IL-2 or placebo for the first 3 months of the study. During this time, participants will continue on their current antiretroviral medications and have monthly study visits. Study visits will include a brief medical interview and physical exam, administration of the vaccine, and blood tests. At the end of 3 months, participants will discontinue both their study medications (IL-2 and ALVAC or placebo) and their antiretroviral medications. This Diagnostic Treatment Interruption (DTI) will continue for a minimum of 3 months. During the DTI, participants will have weekly study visits in which viral and lymphocyte dynamics are monitored.
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- NY Presbyterian Weill Cornell Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- HIV infected
- Stable HAART, defined as two or more antiretroviral drugs in combination. Changes in drugs are allowed if for any reason other than virologic failure.
- CD4 cell count > 200 cells/ml for the 12 months prior to enrollment
- CD4 cell count >= 400 cells/ml on two successive occasions at least 14 days apart within 30 days of study entry
- HIV RNA < 2 million copies/ml, with suppression on HAART to < 50 copies/ml on two successive occasions at least 14 days apart within 30 days of entry
- Acceptable methods of contraception
Exclusion Criteria
- Current AIDS-defining illness
- Virologic failure (HIV RNA > 10,000 copies/ml) while receiving current HAART regimen
- Immunomodulating agents, including interleukins; antibodies reactive with lymphocytes, monocytes, or antigen presenting cells; and polyribonucleotides
- IL-2 therapy within 4 weeks of study entry
- Uncontrolled active cardiac, renal, pulmonary, hepatic, or CNS disease
- History of active malignancy requiring chemotherapy
- History of thyroid disease or autoimmune disorders, including asthma, inflammatory bowel disease, rheumatoid arthritis, and psoriasis
- Active infection with hepatitis B virus or hepatitis C virus
- Severe retinopathy due to diabetes, hypertension, CMV, or macular degeneration
- Serious infection or other serious medical illness that is potentially life threatening and requires systemic therapy and/or hospitalization within 14 days of study entry
- Substance abuse that will compromise the participant's ability to adhere to the study requirements
- Current alcohol use of more than 1 drink/day any time during 6 months prior to study entry. One drink is defined as 12 ounces of beer, 5 ounces of wine, or 1.25 ounces of hard liquor.
- History of allergy to eggs, IL-2, or other components of the vaccine or IL-2 formulation
- Pregnant or breast-feeding
- Professionals working in close contact with canaries (e.g., breeding farms, bird shops)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Mean log10 viral load for each experimental group from the average of 5 values obtained during Weeks 21 to 25, corresponding to 8 to 12 weeks following the interruption of HAART
|
Secondary Outcome Measures
Outcome Measure |
---|
Proportion of subjects who relapse during the first 12 weeks following cessation of HAART
|
length of time to the termination of Step II
|
changes in frequency, activation state, and HIV-specific functional capacity of T cells and NK cells in blood, as monitored by the expression of intracellular cytokines during the first 12 weeks after cessation of HAART
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kendall A. Smith, MD, Weill Medical College of Cornell University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antineoplastic Agents
- Interleukin-2
Other Study ID Numbers
- 1R01AI051181-01A1 (U.S. NIH Grant/Contract)
- 0900-397
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Interleukin-2
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of Michigan Rogel Cancer CenterUniversity of MichiganTerminated
-
Loma Linda UniversityWithdrawnMelanoma | Metastatic Kidney CancerUnited States
-
City of Hope Medical CenterCompletedGlioblastoma | Brain Tumor | Gliosarcoma | Anaplastic Astrocytoma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Giant Cell Glioblastoma | Anaplastic Meningioma | Mixed Glioma | Brain Stem Glioma | Ependymoblastoma | Grade III Meningioma | Meningeal Hemangiopericytoma | Pineal Gland AstrocytomaUnited States
-
Assistance Publique - Hôpitaux de ParisIltoo PharmaActive, not recruitingRecurrent MiscarriageFrance
-
National Heart, Lung, and Blood Institute (NHLBI)Completed
-
French National Agency for Research on AIDS and...Chiron CorporationCompleted
-
National Cancer Institute (NCI)TerminatedRecurrent NeuroblastomaUnited States
-
Icahn School of Medicine at Mount SinaiCompletedCommon Variable Immunodeficiency
-
Aalborg University HospitalUnknownHIV Infections | Hepatitis B | Hepatitis ADenmark